GleamWall
中文EN

CRDF Cardiff Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213037 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.6%
TTM net income YoY25.3%
TTM EPS YoY31.6%
Revenue 3-yr CAGR6.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-7,068.2%
Net margin-6,735.2%
FCF margin—
EBITDA margin-7,005.5%

Returns

ROE-97.9%
ROA-75.2%
ROIC (approx.)-114.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets22.8%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.06x
Accruals ratio4.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$593,000$683,000
R&D expense$35.33M$36.85M
SG&A expense$14.22M$12.48M
Operating income-$48.96M-$48.65M
Pretax income-$45.85M-$45.43M
Income tax$0$0
Net income-$45.85M-$45.43M
EBITDA-$48.60M-$48.25M
EPS (basic)-0.69-0.95
EPS (diluted)-0.69-0.95
Weighted avg. shares (diluted)66.84M47.65M
Balance sheet
Cash & equivalents$17.47M$51.47M
Short-term investments$40.83M$40.28M
Receivables$182,000$773,000
Current assets$60.13M$95.05M
PP&E, net$578,000$898,000
Total assets$61.88M$97.19M
Current liabilities$16.39M$13.43M
Total liabilities$16.50M$14.24M
Shareholders' equity$45.39M$82.95M
Shares outstanding68.31M66.52M
Cash flow statement
Operating cash flow-$37.92M-$37.69M
Capital expenditure$44,000$80,000
Free cash flow-$37.97M-$37.77M
Investing cash flow$1.34M$13.73M
Financing cash flow$2.58M$53.78M
Depreciation & amortization$364,000$404,000
Stock-based compensation$5.69M$4.76M

Free plan shows the latest 2 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.